GlassScriptPhysician profile
Angela Frantsi
NPI 1033682588
$1,592.76
in general payments reported to CMS, 2019-2025
16 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $259 · 2022: $412 · 2023: $534 · 2024: $260 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $920.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $441.15 | 2021-2025 | Wegovy, Saxenda, Ozempic |
| Lilly USA, LLC | $351.77 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $154.62 | 2021-2025 | Breztri, Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $151.56 | 2022 | |
| Amgen INC. | $102.82 | 2023-2024 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $87.06 | 2021-2022 | |
| Pfizer INC. | $70.43 | 2021-2024 | |
| Exact Sciences Corporation | $55.41 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.82 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $22.04 | 2022 | |
| Impel Pharmaceuticals INC. | $21.56 | 2023 | Trudhesa |
| Ultragenyx Pharmaceutical INC. | $18.93 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.52 | 2021 | |
| Ibsa Pharma INC. | $15.28 | 2023 | Tirosint, Licart |
| Currax Pharmaceuticals LLC | $14.98 | 2025 | Contrave, Onzetra Xsail |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Frantsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.